Pre-Filled Syringes: World Industry and Market Prospects 2014-2024 - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

Report Details

Your guide to trends and sales potential for prefillable syringe products

What are the commercial prospects for pre-filled syringes and related technologies? Visiongain's report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our new study analyses those technologies and their therapeutic applications. You will find projected sales to 2024 at overall world market, submarket, injected drug and national level.

In addition to an overall world revenue forecast for pre-filled syringe products, you will see forecasting of world-level submarkets to 2024:
• Glass pre-filled syringes
• Plastic (polymer) pre-filled syringes
• Pen injectors and Autoinjectors

Also, you receive a world unit sales forecast for those medical injection units. Discover qualitative analyses (SWOT and STEP), company profiles, R&D and commercial developments. Moreover, you will gain 60 figures, 79 tables and three interviews with authorities in the industry.

Prospects for leading countries shown to 2024

Regulatory, demographic and commercial developments worldwide will influence the market, especially fast-rising demand in emerging markets.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• US
Japan
Germany,
France,
• UK,
Italy
Spain
Brazil,
Russia,
India
China

Increasing development and use of biological drugs (biologics) will increase worldwide sales of these drug delivery technologies from 2014 to 2024, our study shows.

What issues decide the future of the industry and market?

Our study lets you assess industry trends and outlooks. You find discussions of many issues and developments, including R&D:
• Cost savings and efficiencies
• Plastic disposable syringes and components
• Glass single-use syringes and related parts
• Syringe technology, needles, materials and compound stability
• Safety and convenience issues for injection devices
• Product differentiation and customisation
• Reimbursement and legislation

Our investigation gives you multi-level business research and analysis with sales forecasts. You see how that industry and market can perform from 2014 to 2024.

You will discover prospects for applications of prefillable syringe technologies

Our report also analyses applications of pre-filled drug delivery technologies - medical products. You will discover world-level revenue forecasting for several drug classes to 2024 including:
• Insulins
• Growth hormones
• Low molecular weight heparins (LMWHs)
• Vaccines
• Biosimilar and follow-on protein products

Also, how will 11 injectable drugs - including Lantus, Humalog, NovoLog, Humira and Enbrel - perform from 2014? You will find the potential revenues for these drugs to 2024.

Market Size and Growth Prospects

What does the future hold? Overall revenues from pre-filled syringes will rise from 2014 to 2024, our report forecasts. Improved drug delivery and new formulations will be vital to pharmaceutical companies, increasing demand for innovative medical injection devices.

In 2012, 2.96 billion of those syringe units sold. Pre-filled syringes form one of the fastest growing markets in healthcare.

Safety, stability, convenience and cost-effectiveness benefit unit sales and revenues. Our analyses predict strong revenue growth to 2024 for those medical devices and their applications in human therapy.

Discover profiles for leading companies

Our work profiles leading companies, assessing their technologies and products. You will see activities and outlooks for developers and producers:
• Becton, Dickinson and Company
• Gerresheimer
• SCHOTT
• Ypsomed
• MGlas (Nipro)
• Unilife
• Nuova Ompi (Stevanato Group)
• Weigao
• Roselabs Bioscience
• SHL Group
• Haselmeier
Owen Mumford
• Datwyler
• West Pharmaceutical Services

Our work also discusses companies providing syringe filling machines and associated equipment.

How the Pre-Filled Syringes: World Industry and Market Prospects 2014-2024 report helps you

In summary, our report gives you the following knowledge:
• Revenues to 2024 for the overall world market - discover that industry's prospects, finding promising areas for investments and revenues
• Discover forecasted revenue trends of leading applications
• Find projected revenues of 11 leading therapeutic products to 2024
• Market forecasting to 2024 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), and BRIC countries, India, China, Brazil and Russia
• Assess 14 leading companies, and other players, discovering activities and outlooks
• Competition and opportunities - see what affects the pre-filled syringe market, learning what shapes its future, especially prospects for sustaining and developing business
• Opinions from our survey, seeing interviews with industry authorities.

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

1. Executive Summary

1.1 Pre-Filled Syringes: World Market Outlook 2014-2024
1.2 Report Contents
1.2.1 Benefits of this Report
1.3 Report Methodology
1.3.1 Who is this Report for?
1.3.2 Defining the Pre-Filled Syringe Market

2. An Introduction to the Pre-Filled Syringe Market

2.1 A Brief History of Pre-Filled Syringes
2.2 Design and Manufacture of Pre-Filled Syringes
2.2.1 Glass and Plastic Syringes
2.2.2 Safety and the Pre-Filled Syringe Market
2.2.2.1 Concerns over Needlestick Injuries
2.3 An Introduction to Pen Injectors and Autoinjectors
2.3.1 Pen Injectors and Autoinjectors Offer Advantages in Self-Administration
2.3.2 What Determines Injection Device Choice?
2.4 Future Directions for Pre-Filled Syringes

3. Pre-Filled Syringes: World Market Outlook and Forecast 2014-2024

3.1 The World Pre-Filled Syringe Market 2012-2013
3.1.1 Rapid Growth in Demand and Revenues in the Last Decade
3.1.2 Pre-Filled Syringes as a Share of the Global Drug Delivery Market
3.1.3 Pre-Filled Syringe Market Breakdown by Device 2012
3.2 Growth in the Pre-Filled Syringe Market 2014-2024
3.2.1 Pre-Filled Syringe Market Forecast 2014-2024
3.2.2 Pre-Filled Syringe Unit Sales Forecast 2014-2024
3.2.3 Biologics and Other Market Drivers for this Decade
3.2.3.1 Market Genericisation and Pre-Filled Syringes
3.2.3.2 The Injectable Drug Pipeline is Long
3.2.4 What Will Restrain Market Growth to 2024?
3.2.5 Leading Submarket Revenue Shares 2014-2024
3.3 The Glass Pre-Filled Syringe Submarket 2014-2024
3.3.1 Steady Growth for the Glass Pre-Filled Syringe Submarket 2014-2024
3.3.2 New Manufacturing Processes to Drive Submarket Growth to 2024
3.4 The Plastic Pre-Filled Syringe Submarket 2014-2024
3.4.1 Rapid Growth Forecast for the Plastic Pre-Filled Syringe Submarket to 2024
3.4.2 Plastic Pre-Filled Syringe Submarket Drivers and Restraints 2014-2024
3.5 The Pen Injector and Autoinjector Submarket 2014-2024
3.5.1 Growth in the Pen Injector and Autoinjector Submarket to 2024
3.5.2 High Demand for Simplified Self-Administration Devices
3.5.3 Insulin and Other Biologics to Lead Market Growth

4. Leading National Markets for Pre-Filled Syringes 2014-2024

4.1 Leading National Markets for Pre-Filled Syringes 2012-2013
4.2 National Pre-Filled Syringe Market Forecasts 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Pre-Filled Syringe Market Forecast 2014-2024
4.3.1 New Drug and Device Launches to Drive Growth to 2024
4.4 Leading EU Nations: National Pre-Filled Syringe Submarket Forecasts 2014-2024
4.4.1 Biosimilars and Growth in the EU Pre-Filled Syringe Submarket 2014-2024
4.5 Pre-Filled Syringes in Japan: Market Outlook and Forecast 2014-2024
4.6 Pre-Filled Syringes in Emerging Markets 2014-2024
4.6.1 Pre-Filled Syringe Manufacturers Are Investing in Emerging Markets
4.6.2 China: The Leading Emerging Pre-Filled Syringe Submarket 2014-2024
4.6.3 India: Double-Digit Growth Forecast 2014-2024
4.6.4 Brazil: Biologics Growth to Lead to Higher Demand for Pre-Filled Syringes 2014-2024
4.6.5 Russia: Submarket Forecast 2014-2024

5. Outlook for Leading Therapeutic Sectors for Pre-Filled Syringes 2014-2024

5.1 Leading Therapeutic Sectors for Pre-Filled Syringes and Other Injection Devices 2012-2013
5.1.1 Vaccines and Heparins Are Major Market Sectors 2012-2013
5.1.2 Rising Demand in Chronic Conditions: Autoimmune Diseases and Diabetes
5.1.3 Growth for Key Market Sectors 2014-2024
5.2 Pre-Filled Syringes and Pen Injectors for Diabetes 2014-2024
5.2.1 Insulin Market Forecast 2014-2024
5.2.2 High Rates of Pen Injector Use in the EU and Japan
5.2.3 Insulin Pumps: A Technology to Challenge Pen Injectors to 2024?
5.2.4 The Prospects for Biosimilar Insulin in Developed and Emerging Markets
5.2.4.1 Injection Devices for Biosimilar Insulin Products
5.3 Rheumatoid Arthritis: Leading Biologics Dominate the Market 2013
5.3.1 Rheumatoid Arthritis Market Forecast 2014-2024
5.3.2 All Major Injectable Therapies Are Marketed in Proprietary Devices
5.3.3 Novel Injection Systems for RA: Meeting the Needs of Patients
5.3.4 The Threat from Oral Therapies to 2024
5.4 Self-Injection for Multiple Sclerosis: Outlook 2014-2024
5.4.1 Multiple Sclerosis Market Forecast 2014-2024
5.4.2 Reusable Autoinjectors for Interferon Beta Therapy
5.4.3 Oral Therapies to Drive MS Market Growth in this Decade
5.5 Growth Hormones Market Outlook and Forecast 2014-2024
5.5.1 Growth Hormone Market Forecast 2014-2024
5.5.2 Biosimilar Growth Hormones and Pen Injectors
5.5.3 Uptake of Needle-Free Injectors for Growth Hormone Administration
5.6 Pre-Filled Heparin Syringes 2014-2024
5.6.1 One Brand Leads the Heparin Market, 2012-2013
5.6.2 Pre-Filled Syringes for LMWHs
5.6.3 Heparin Market Forecast 2014-2024
5.6.4 Follow-On Heparins: Biosimilars or Generics?
5.7 The Vaccine Market Outlook 2014-2024
5.7.1 Vaccine Market Forecast 2014-2024
5.7.2 Single-Use Devices for Vaccine Delivery
5.7.2.1 BD Uniject: A Private-Public Collaboration
5.7.3 Needle-Free Injectors for Vaccines

6. Leading Pre-Filled Device Therapies 2014-2024

6.1 Leading Insulin Therapies Using Pen Injectors 2014-2024
6.1.1 Lantus: The World's Bestselling Insulin Analogue
6.1.1.1 SoloSTAR, ClikSTAR and AllSTAR: Three Pen Injectors for Lantus
6.1.1.2 Outlook for Lantus 2014-2024
6.1.2 NovoLog: The Leading Fast-Acting Insulin
6.1.2.1 NovoLog FlexPen: Room Temperature Storage for Patient Convenience
6.1.2.2 Faster-Acting Insulin in Development
6.1.3 Humalog
6.1.3.1 Humalog: HumaPen and KwikPen
6.1.3.2 Humalog Revenue Forecast 2014-2024
6.2 Top Biologics for Rheumatoid Arthritis: Device Outlook to 2024
6.2.1 Humira: The Biggest Selling Drug in 2012
6.2.1.1 The Humira Pen Is an Innovative Delivery Device
6.2.1.2 Steady Revenue Growth for Humira to 2017
6.2.2 Enbrel
6.2.2.1 Pre-Filled Injection Devices Available for Enbrel 2013
6.2.2.2 Protected from Biosimilars for this Decade?
6.3 Multiple Sclerosis: Leading Injectable Therapies 2014-2024
6.3.1 Copaxone: An Injectable Non-Interferon Therapy
6.3.1.1 Copaxone Uses the Autoject 2 Autoinjector from Owen Mumford
6.3.1.2 Next-Generation Copaxone and Generics Expected in 2014
6.3.2 Avonex
6.3.2.1 Biogen Idec Launches the Avonex Pen 2011
6.3.2.2 Outlook for Avonex 2014-2024
6.3.3 Rebif
6.3.3.1 Self-Injection Options for Rebif: Rebiject II, RebiSmart and RebiDose
6.3.3.2 Rebif: A Similar Outlook to Avonex to 2024?
6.4 Two Growth Hormones Dominate the Market 2013
6.4.1 Norditropin: Outlook 2014-2024
6.4.2 Genotropin: Outlook and Revenue Forecast 2014-2024
6.5 Outlook for Leading Heparin Products 2014-2024
6.5.1 Lovenox: Generic Competition in the US Since 2010
6.5.1.1 Lovenox: Revenue Forecast 2014-2024
6.5.2 Arixtra and Fragmin

7. Pre-Filled Syringes: Industry Trends 2014-2024

7.1 Pre-Filled Syringes Market: Strengths and Weaknesses 2012-2013
7.1.1 Pre-Filled Syringes Offer Many Benefits Over Other injection Technologies
7.2 Pre-Filled Syringes Market: Opportunities and Threats 2014-2024
7.2.1 Pre-Filled Syringes Face Challenges from Other Technologies
7.3 Pre-Filled Syringes Market: STEP Analysis 2014-2024
7.3.1 Social Factors: Rising Disease Incidence and Demand for At-Home Care
7.3.2 Technological Developments: Improved Safety and Administration
7.3.3 Economic Pressures: Pre-Filled Syringes Are Cost Efficient
7.3.3.1 High Barriers to Market Entry Exist
7.3.4 Political Issues: Regulatory Developments for Pre-Filled Syringes
7.4 Regulatory and Safety Outlook for Pre-Filled Syringes 2014-2024
7.4.1 Needlestick Safety and Prevention
7.4.2 International Regulations for Needlestick Prevention
7.4.2.1 The US: The First Country to Introduce Needlestick Legislation
7.4.2.2 The EU: New Rules from 2013 Onwards
7.4.2.3 Needlestick Safety in Japan 2014-2024
7.4.2.4 Legislation for Needlestick Safety in Emerging Markets
7.4.3 Manufacturers Will Continue to Develop New Devices for Needlestick Prevention
7.4.3.1 Ancillary versus Integrated Safety Devices
7.4.4 Extractables and Leachables
7.4.4.1 Companies Will Reduce Sources of Extractables and Leachables
7.4.5 Products that Minimise Extractables and Leachables
7.4.5.1 Protein Aggregation: The Challenge of Biological Drugs
7.4.5.2 Regulatory Requirements for Extractables and Leachables 2013
7.5 Biologics and the Pre-Filled Syringes Market 2014-2024
7.5.1 Manufacturing Pre-Filled Syringes for Biologics: Glass versus Plastic
7.5.2 Biologics Provide New Challenges for Device Manufacturers
7.5.2.1 Lyophilised Drugs and Dual-Chamber Devices
7.5.3 Delivery Opportunities for High Viscosity Drugs
7.5.4 Are Biosimilars an Opportunity for Pre-Filled Syringe Manufacturers?
7.6 The Role of Patients in Pre-Filled Syringe Industry Development and Growth
7.6.1 Chronic Disease Incidence 2014-2024
7.6.2 The Rise in At-Home Care
7.6.3 Improving Patient Adherence
7.6.4 Injection Devices Must be Developed for Patient Convenience: Human Factor Engineering
7.7 Technological Developments in Pre-Filled Syringes to 2024
7.7.1 Product Differentiation Will be Vital in Crowded Treatment Markets
7.7.1.1 Product Customisation: Adapting Injection Devices
7.7.2 Trends in Manufacturing Materials for Pre-Filled Syringes
7.7.3 Competing Technologies Will Challenge Pre-Filled Syringes
7.7.3.1 Will Needle-Free Devices Become a Significant Competing Technology?
7.7.3.2 Patients Prefer Oral Drug Delivery
7.8 Outsourcing in the Pre-Filled Syringe Industry
7.8.1 Contract Medical Device Manufacturing
7.8.2 Contract Filling of Pre-Filled Syringes

8. Leading Pre-Filled Syringe and Related Technology Manufacturers 2013

8.1 Leading Pre-Filled Syringe Manufacturers 2013
8.1.1 BD Is the Clear Market Leader
8.1.1.1 New Product Launches 2013
8.1.1.2 Outlook for BD's Pre-Filled Syringes 2014-2024
8.1.2 Gerresheimer: Glass and Plastic Syringes and Pen Injectors
8.1.2.1 Gerresheimer: Recent Performance and Outlook
8.1.3 Schott
8.1.3.1 Schott Reports Rising Demand for Plastic Syringes
8.1.4 Nipro Is a Market Leader through its MGlas Acquisition
8.1.5 Nuova Ompi
8.1.5.1 Expansion Planned to 2016
8.1.6 Emerging Market Players
8.1.6.1 Weigao: Pre-Filled Syringes for China and Beyond
8.1.6.2 Unilife: Pre-Filled Safety Syringes
8.1.6.3 Roselabs Entered the Market in 2012
8.2 Leading Pen Injector and Autoinjector Manufacturers 2013
8.2.1 SHL Group
8.2.1.1 Growth for SHL Group 2014-2024
8.2.2 Ypsomed
8.2.2.1 Pen Injector Revenue Returning to Growth in 2014
8.2.3 Haselmeier
8.2.3.1 Haselmeier Is Looking to Expand Globally
8.2.4 Owen Mumford
8.2.4.1 Outlook for Owen Mumford 2014-2024
8.2.5 Other Leading and Emerging Autoinjector Manufacturers
8.3 Leading Pre-Filled Syringe Component Manufacturers 2013
8.3.1 Datwyler
8.3.1.1 Datwyler: Growth Prospects 2014-2024
8.3.2 West Pharmaceutical Services
8.3.2.1 Expanding Manufacturing in Emerging Markets

9. Expert Opinion

9.1 Richard Harrison, Business Development Manager, Injectables, Bespak Europe
9.1.1 Bespak
9.1.2 Unmet Needs and Future Directions for Autoinjectors
9.1.3 Challenges in Developing Autoinjectors
9.1.4 Trends from Drug Development Impacting Device Manufacturers
9.2 David Daily, Director R&D and BD, Injectable Delivery Devices, Elcam Medical and CEO, DALI Medical Devices
9.2.1 Elcam Medical
9.2.2 Key Unmet Needs and Challenges for Pre-Filled Syringes and Autoinjectors
9.2.3 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
9.2.4 Growth in the Pre-Filled Syringe Market to 2024
9.3 West Pharmaceutical Services
9.3.1 Changes in Demand for Pre-Filled Syringes
9.3.2 Future Expectations for the Pre-Filled Syringe Market
9.3.3 The Role of Emerging Markets in Pre-Filled Syringe Growth
9.3.4 Drug Development Trends Impacting Device Manufacturers to 2024

10. Conclusions from our Study

10.1 Pre-Filled Syringe Market Overview 2012-2013
10.1.1 Glass Syringes Dominate in 2013
10.2 Pre-Filled Syringe Market Growth 2014-2024
10.2.1 Commercial Drivers for Pre-Filled Syringes
10.3 The Future of Pre-Filled Injection Devices

List of Tables

Table 1.1 Currency Exchange Rates
Table 3.1 Pre-Filled Syringe Market: Revenue ($bn) and Units (bn), 2012-2013
Table 3.2 Pre-Filled Syringe Market by Sector: Revenue ($bn) and Units (bn), 2012
Table 3.3 Pre-Filled Syringe Market: Overall Market and Revenue Forecasts ($bn) by Sector, 2012-2024
Table 3.4 Pre-Filled Syringe Market: Overall Market Unit Forecasts (bn) by Sector, 2012-2024
Table 3.5 Pre-Filled Syringe Market Revenue: Submarket Shares (%), 2012-2024
Table 3.6 Glass Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024
Table 3.7 Selected Proprietary Polymers for Plastic Pre-Filled Syringes, 2013
Table 3.8 Plastic Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024
Table 3.9 Pen Injector and Autoinjector Submarket: Revenue Forecast ($bn), 2012-2024
Table 4.1 Pre-Filled Syringe Market: Revenues ($bn) by Country, 2012-2013
Table 4.2 Pre-Filled Syringe Market: Regional and National Submarket Revenue Forecasts ($bn), 2012-2024
Table 4.3 Pre-Filled Syringe Market: National Submarket Shares (%)
Table 4.4 US Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Table 4.5 European Pre-Filled Syringe Market: Leading National Submarket Revenue Forecasts ($bn), 2012-2024
Table 4.6 Japanese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Table 4.7 Chinese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Table 4.8 Indian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Table 4.9 Brazilian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Table 4.10 Russian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Table 5.1 Pen Manufacturing Agreements for Leading Insulin Brand Manufacturers, 2013
Table 5.2 Selected Biosimilar Insulin Pen Injectors, 2013
Table 5.3 Insulin Market: Revenue Forecast ($bn), 2012-2024
Table 5.4 Rheumatoid Arthritis Market: Revenue Forecast ($bn), 2012-2024
Table 5.5 Interferon Beta Therapies for MS, 2013
Table 5.6 Oral Therapies Launched for MS, 2010-2013
Table 5.7 Multiple Sclerosis Market: Revenue Forecast ($bn), 2012-2024
Table 5.8 Growth Hormone Market: Revenue Forecast ($bn), 2012-2024
Table 5.9 Selected Emerging Market Biosimilar Growth Hormones, 2013
Table 5.10 Heparin Market: Revenue Forecast ($bn), 2012-2024
Table 5.11 Vaccine Market by Company: Revenues ($bn), 2012
Table 5.12 Vaccines Market: Revenue Forecast ($bn), 2012-2024
Table 6.1 Leading Pre-Filled Insulin Therapies: Revenues ($bn), 2008-2012
Table 6.2 Lantus: Revenue Forecast ($bn), 2012-2024
Table 6.3 NovoLog: Revenue Forecast ($bn), 2012-2024
Table 6.4 Humalog: Revenue Forecast ($bn), 2012-2024
Table 6.5 Leading Pre-Filled Rheumatoid Arthritis Therapies: Revenues ($bn), 2010-2012
Table 6.6 Humira: Revenue Forecast ($bn), 2012-2024
Table 6.7 Enbrel: Revenue Forecast ($bn), 2012-2024
Table 6.8 Leading Pre-Filled Multiple Sclerosis Therapies: Revenues ($bn), 2008-2012
Table 6.9 Copaxone: Revenue Forecast ($bn), 2012-2024
Table 6.10 Avonex: Revenue Forecast ($bn), 2012-2024
Table 6.11 Rebif: Revenue Forecast ($bn), 2012-2024
Table 6.12 Leading Pre-Filled Growth Hormone Therapies: Revenues ($bn), 2010-2012
Table 6.13 Norditropin: Revenue Forecast ($bn), 2012-2024
Table 6.14 Genotropin: Revenue Forecast ($bn), 2012-2024
Table 6.15 Leading Pre-Filled Heparins: Revenues ($bn), 2010-2012
Table 6.16 Lovenox: Revenue Forecast ($bn), 2012-2024
Table 7.1 Pre-Filled Syringe Market: Strengths and Weaknesses, 2012-2013
Table 7.2 Benefits and Weaknesses to Pre-Filled Syringes as an Injectable Delivery Device, 2013
Table 7.3 Pre-Filled Syringe Market: Opportunities and Threats, 2014-2024
Table 7.4 Pre-Filled Syringe Market: STEP Analysis, 2014-2024
Table 7.5 Leading Market Participants: Broad Product Portfolios, 2013
Table 7.6 Hepatitis B and C: Prevalence by Country, 2013
Table 7.7 Selected Safety Products for Pre-Filled Syringes, 2013
Table 7.8 Selected Pre-Filled Injection Devices for Lyophilised Drugs, 2013
Table 7.9 Leading Blockbuster Biologic Patent Expiries in the US and EU, 2013-2028
Table 7.10 Pre-Filled Syringe Manufacturers: Alternative Injectable Technologies, 2013
Table 7.11 Selected Insulin Pumps Available, 2013
Table 7.12 Oral Drug Competitors for Leading Pre-Filled Syringe Therapeutic Sectors, 2014-2024
Table 7.13 Selected Leading CMOs: Pre-Filled Syringe Filling Capabilities, 2013
Table 8.1 BD: Pre-Filled Injection Systems, 2013
Table 8.2 BD Medical - Pharmaceutical Systems: Revenue ($bn), 2008-2012
Table 8.3 Gerresheimer: Revenue ($bn) by Division, 2010-2012
Table 8.4 Schott: Revenue ($bn), 2011-2012
Table 8.5 Weigao: Pre-Filled Syringe Revenue ($m) and Production Volume, 2010-2012
Table 8.6 Unilife: Pre-Filled Syringe Product Portfolio, 2013
Table 8.7 Unilife: Revenue ($m), 2008-2013
Table 8.8 SHL Group: Pen Injector and Autoinjector Portfolio, 2013
Table 8.9 Ypsomed: Pen Injector and Autoinjector Portfolio, 2013
Table 8.10 Ypsomed Delivery Devices: Revenue ($bn), 2009-2013
Table 8.11 Haselmeier: Pen Injector and Autoinjector Portfolio, 2013
Table 8.12 Owen Mumford: Pen Injector and Autoinjector Portfolio, 2013
Table 8.13 Owen Mumford: Revenue ($bn), 2009-2012
Table 8.14 Datwyler Pharma Packaging: Revenue ($bn), 2007-2012
Table 8.15 West Pharmaceutical Services: Revenue ($bn) by Division, 2009-2012
Table 9.1 Bespak: Needle-Free Injectors, 2013
Table 10.1 Pre-Filled Syringe Market: Revenue Forecasts ($bn) and Market Shares (%) by Sector, 2012-2024
Table 10.2 Pre-Filled Syringe Market: Revenue Forecasts ($bn) and Market Shares (%) by Region, 2012-2024

List of Figures

Figure 2.1 Key Events in the Pre-Filled Syringe Market History, 1954-2000
Figure 2.2 Major Trends for Pre-Filled Syringe Market Growth, 2014-2024
Figure 3.1 Pre-Filled Syringe Market: Revenue ($bn) and Units (bn), 2012-2013
Figure 3.2 Pre-Filled Syringe Market: Revenue Share (%) by Sector, 2012
Figure 3.3 Pre-Filled Syringe Market: Unit Share (%) by Sector, 2012
Figure 3.4 Pre-Filled Syringe Market Forecast ($bn), 2012-2024
Figure 3.5 Pre-Filled Syringe Market Unit Forecast (bn), 2012-2024
Figure 3.6 Pre-Filled Syringe Unit Share (%) by Sector, 2012-2024
Figure 3.7 Pre-Filled Syringes Market: Drivers, 2014-2024
Figure 3.8 Pre-Filled Syringes Market: Restraints, 2014-2024
Figure 3.9 Pre-Filled Syringe Market Revenue: Submarket Shares (%), 2018
Figure 3.10 Pre-Filled Syringe Market Revenue: Submarket Shares (%), 2024
Figure 3.11 Glass Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024
Figure 3.12 Glass Pre-Filled Syringe Submarket: Drivers and Restraints, 2014-2024
Figure 3.13 Plastic Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024
Figure 3.14 Plastic Pre-Filled Syringe Submarket: Drivers and Restraints, 2014-2024
Figure 3.15 Pen Injector and Autoinjector Submarket: Revenue Forecast ($bn), 2012-2024
Figure 3.16 Pen Injector and Autoinjector Submarket: Drivers and Restraints, 2014-2024
Figure 4.1 Pre-Filled Syringe Market: Revenues ($bn) by Region, 2012-2013
Figure 4.2 Pre-Filled Syringe Market: National Submarket Shares (%), 2018
Figure 4.3 Pre-Filled Syringe Market: National Submarket Shares (%), 2024
Figure 4.4 US Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Figure 4.5 French and German Pre-Filled Syringe Submarket Forecasts ($bn), 2012-2024
Figure 4.6 Italian, UK and Spanish Pre-Filled Syringe Submarket Forecasts ($bn), 2012-2024
Figure 4.7 Japanese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Figure 4.8 Chinese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Figure 4.9 Indian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Figure 4.10 Brazilian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Figure 4.11 Russian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024
Figure 5.1 Insulin Market: Revenue Forecast ($bn), 2012-2024
Figure 5.2 Rheumatoid Arthritis Market: Revenue Forecast ($bn), 2012-2024
Figure 5.3 Multiple Sclerosis Market: Revenue Forecast ($bn), 2012-2024
Figure 5.4 Growth Hormone Market: Revenue Forecast ($bn), 2012-2024
Figure 5.5 Heparin Market: Revenue Forecast ($bn), 2012-2024
Figure 5.6 Vaccines Market: Revenue Forecast ($bn), 2012-2024
Figure 6.1 Lantus: Revenue Forecast ($bn), 2012-2024
Figure 6.2 NovoLog: Revenue Forecast ($bn), 2012-2024
Figure 6.3 Humalog: Revenue Forecast ($bn), 2012-2024
Figure 6.4 Humira: Revenue Forecast ($bn), 2012-2024
Figure 6.5 Enbrel: Revenue Forecast ($bn), 2012-2024
Figure 6.6 Copaxone: Revenue Forecast ($bn), 2012-2024
Figure 6.7 Avonex: Revenue Forecast ($bn), 2012-2024
Figure 6.8 Rebif: Revenue Forecast ($bn), 2012-2024
Figure 6.9 Norditropin: Revenue Forecast ($bn), 2012-2024
Figure 6.10 Genotropin: Revenue Forecast ($bn), 2012-2024
Figure 6.11 Lovenox: Revenue Forecast ($bn), 2012-2024
Figure 7.1 Hepatitis B and C: Prevalence by Country, 2013
Figure 7.2 World Biologics Market: Revenue Forecast ($bn), 2012-2024
Figure 7.3 World Biosimilars Market: Revenue Forecast ($bn), 2012-2024
Figure 8.1 BD Medical - Pharmaceutical Systems: Revenue ($bn), 2008-2012
Figure 8.2 Gerresheimer: Revenue ($bn) by Division, 2010-2012
Figure 8.3 Schott: Revenue ($bn), 2011-2012
Figure 8.4 Weigao: Pre-Filled Syringe Revenue ($m) and Production Volume, 2010-2012
Figure 8.5 Unilife: Revenue ($m), 2008-2013
Figure 8.6 Ypsomed Delivery Devices: Revenue ($bn), 2009-2013
Figure 8.7 Owen Mumford: Revenue ($bn), 2009-2012
Figure 8.8 Datwyler Pharma Packaging: Revenue ($bn), 2007-2012
Figure 8.9 West Pharmaceutical Services: Revenue ($bn) by Division, 2009-2012
Figure 10.1 Pre-Filled Syringe Market: Revenue Forecast ($bn) by Sector, 2012-2024
Figure 10.2 Pre-Filled Syringe Market: Revenue Forecast ($bn) by Region, 2012-2024

Companies Listed

AbbVie
Accu-Chek (part of Roche)
Aché
Aesica Pharmaceuticals
AI Biosciences
Albany Molecular Research Inc (AMRI)
Althea Technologies
Amega Biotech
Amgen
Animas
Antares Pharma
Aptar Pharma (part of AptarGroup)
Aptar Stelmi (part of AptarGroup)
AptarGroup
Batelle
Baxter BioPharma Solutions
Bayer
Becton, Dickinson & Co. (BD)
Berlin-Chemie (part of Menarini Group)
Bespak
Biocon
BioConnection
Biodel
Biogen Idec
Bioject Medical Technologies
Biosidus
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)
Bristol-Myers Squibb
Cambridge Consultants
Carl Zeiss Foundation
Catalent Pharma Solutions
Centers for Disease Control and Prevention (CDC)
China Food and Drug Administration (CFDA)
Cipla
Consort Medical
Cosmo Pharmaceuticals
Crossject
Daikyo Seiko
DALI Medical Devices
Datwyler
Disetronic Group (part of Roche)
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Duoject Medical Systems
Eisai
Elcam Medical
Eli Lilly
Emisphere
European Medicines Agency (EMA)
FDA Office of Device Evaluation [US]
Ferring Pharmaceuticals
Future Injection Technologies (FIT)
Gan & Lee Pharmaceuticals
GAVI Alliance
Genentech (part of Roche)
GeneScience Pharmaceuticals (GenSci)
Gerresheimer
GSK
Haselmeier
Haselmeier Inc. (part of Haselmeier)
Hospira
Hospira One2One (part of Hospira)
Hyaluron Contract Manufacturing (HCM, part of AMRI)
Incepta Pharmaceuticals
Insulet
J&J
Jabil Circuit
Janssen Biotech (part of J&J)
Johns Hopkins University
LG Life Sciences
Marvel Life Sciences
Massachusetts Institute of Technology (MIT)
Medimop Medical Projects (part of West)
Medtronic
Merck & Co.
Merck Serono (part of Merck KGaA)
MG Sterile Products (part of Nipro)
MGlas (part of Nipro)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Ministry of Labour and Employment [Brazil]
Mitsubishi Tanabe Pharma
National Health Service (NHS) [UK]
Nektar Therapeutics
Nipro
Novartis
Novo Nordisk
Nuova Ompi (part of Stevanato Group)
Nypro (part of Jabil Circuit)
Occupational Safety and Health Administration (OSHA) [US]
Optrel (part of Stevanato Group)
Oval Medical
Owen Mumford
PA Consulting Group
PATH
Pfizer
PharmaJet
Pharmstandard
Phillips Medisize
Plastef Investissements
Polfa-Tarchomin
Primequal
Revolutions Medical
Rexam
Roche
Roselabs
Roselabs Bioscience (part of Roselabs)
ROVI CM
Safety Syringes (part of BD)
Sandoz (part of Novartis)
Sanofi
Sanofi Pasteur
Savient Pharmaceuticals
Schering-Plough (part of Merck & Co.)
Schott
Schott Kaisha
Schott Xinkang Pharmaceutical Packaging
SciGen
Shanghai Celgen Bio-Pharmaceutical
Shanghai CP Guojian Pharmaceutical
SHL Group
Spami (part of Stevanato Group)
Specialty Coating Systems (SCS)
Square Pharmaceuticals
Stevanato Group
Swedish Orphan Biovitrum (Sobi)
Taisei Kako
Terumo
Teva Pharmaceutical Industries
The Medical House (part of Bespak)
tip-top
Tonghua Dongbao Pharmaceutical
UCB
UNICEF
Unilife
University of Virginia
US Agency for International Development
US Food and Drug Administration (FDA)
Vetter Pharma
Weigao Group
West Pharmaceutical India Packaging Private (part of West)
West Pharmaceutical Services
Wockhardt
World Health Organization (WHO)
Wyeth (part of Pfizer)
Ypsomed
Zeon Corporation

Read the full report:
Pre-Filled Syringes: World Industry and Market Prospects 2014-2024
http://www.reportbuyer.com/pharma_healthcare/diagnostics/pre_filled_syringes_world_market_prospects_2012_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.